Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma

Bertrand Coiffier1

  • 1CH Lyon-Sud, 69495 Pierre, Bénite, France. bertrand.coiffier@chu-lyon.fr

Current Hematology Reports
|August 7, 2003
PubMed

Monoclonal antibodies have been used as a therapeutic option for patients with lymphoma for less than 5 years, but they have already changed our perception of how to treat these patients. In this review, the use of different types of monoclonal antibodies in the treatment of patients with diffuse large B-cell lymphoma is analyzed, particularly the combination of rituximab with chemotherapy as a first-line therapeutic option. The putative role of other monoclonal antibodies is discussed.

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...